RB Capital Management LLC Increases Stock Position in Abbott Laboratories $ABT

RB Capital Management LLC lifted its holdings in Abbott Laboratories (NYSE:ABT) by 1.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 40,683 shares of the healthcare product maker’s stock after purchasing an additional 518 shares during the period. Abbott Laboratories comprises 1.3% of RB Capital Management LLC’s holdings, making the stock its 19th biggest position. RB Capital Management LLC’s holdings in Abbott Laboratories were worth $5,533,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Hughes Financial Services LLC purchased a new stake in shares of Abbott Laboratories in the 1st quarter worth approximately $27,000. Abound Financial LLC purchased a new stake in Abbott Laboratories during the first quarter valued at approximately $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories during the first quarter valued at approximately $30,000. Wormser Freres Gestion purchased a new stake in Abbott Laboratories during the fourth quarter valued at approximately $32,000. Finally, JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories during the first quarter valued at approximately $32,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ABT shares. Wells Fargo & Company decreased their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research report on Friday, July 18th. Leerink Partners started coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a “market perform” rating and a $143.00 target price for the company. Morgan Stanley increased their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. BTIG Research decreased their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. Finally, Evercore ISI increased their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $144.47.

Abbott Laboratories Stock Up 1.0%

NYSE:ABT opened at $133.92 on Friday. The firm has a market capitalization of $233.08 billion, a P/E ratio of 16.78, a PEG ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company’s fifty day moving average price is $130.41 and its 200-day moving average price is $131.29. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the business earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.